散发性多发性颅内脑膜瘤并不提示患者预后更差:一项病例对照研究结果
该单中心匹配队列研究(2008—2018年)将34例散发性多发性脑膜瘤患者与孤立性脑膜瘤患者1:1匹配,比较干预率、复发、新发脑膜瘤及死亡率,发现两组干预率、WHO 2级比例、无复发生存及总生存均无显著差异,提示散发性多发性脑膜瘤临床结局未必更差。
要点
- 多发性脑膜瘤患者干预率67.6% vs 孤立性70.6%(P=0.792),无显著差异。
- 两组WHO 2级比例34.8% vs 29.2%(P=0.679),无显著差异。
- 中位无复发生存89个月(95%CI 76-104),两组无显著差异(P=0.209)。
核心结论
- 散发性多发性脑膜瘤可能并不导致更差的临床结局。
- 多发性脑膜瘤患者的管理应针对有症状的脑膜瘤或高风险无症状脑膜瘤进行个体化制定。
研究设计与样本
- 单中心匹配队列研究,时间范围为2008—2018年。
- 纳入初诊时同时存在多发性脑膜瘤、无既往颅内放疗史、无同期激素替代治疗、无NF2-神经鞘瘤病特征的患者。
- 符合条件的患者按1:1与孤立性脑膜瘤患者匹配。
- 共纳入34例患者,初诊时携带76个脑膜瘤。
主要发现
- 平均年龄59.3岁(SD=13.5),31例(91.2%)为女性。
- 每例患者脑膜瘤中位数为2个(范围2-6),18例(52.9%)初诊时有症状。
- 中位总随访时间为80.6个月(IQR 44.1-99.6)。
- 与孤立性脑膜瘤患者相比,干预率无差异(67.6% vs 70.6%,P=0.792)。
- 多发性脑膜瘤患者中8例(34.8%)为WHO 2级,孤立性脑膜瘤患者中7例(29.2%)为WHO 2级(P=0.679)。
关键数值与推荐
- 干预率:多发性脑膜瘤组67.6% vs 孤立性脑膜瘤组70.6%(P=0.792)。
- WHO 2级比例:多发性脑膜瘤组34.8% vs 孤立性脑膜瘤组29.2%(P=0.679)。
- 中位无复发生存期:89个月(95%CI 76-104),两组间P=0.209。
- 平均总生存期:132个月(95%CI 127-138),两组间P=0.860。
临床怎么用
- 作者认为,散发性多发性脑膜瘤可能并不导致更差的临床结局。
- 作者建议,多发性脑膜瘤患者的管理应针对有症状的脑膜瘤或高风险无症状脑膜瘤进行个体化制定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sporadic multiple meningioma are uncommon. Population-based data suggests that these patients have a reduced overall survival when compared to patients with solitary meningioma. The aim of this study was to investigate the clinical outcomes in multiple and solitary meningioma. METHODS: A single-center matched cohort study (2008-2018) was performed. Patients with synchronous multiple meningioma at presentation, with no history of prior intracranial radiation, concurrent hormone replacement therapy or features of NF2-schwannomatosis were included. Eligible patients were matched 1:1 to patients with solitary meningioma. Outcomes of interest were occurrence of an intervention, recurrence, new meningioma development and mortality. RESULTS: Thirty-four patients harboring 76 meningioma at presentation were included. Mean age was 59.3 years (SD = 13.5). Thirty-one (91.2%) were female. The median number of meningioma per patient was 2 (range 2-6). Eighteen patients (52.9%) were symptomatic at presentation. Median overall follow-up was 80.6 months (IQR 44.1-99.6). Compared to patients with a sporadic meningioma, there was no difference in intervention rates (67.6% vs 70.6%, P = 0.792). Eight patients (34.8%) with a multiple meningioma had a WHO grade 2 meningioma compared to 7 (29.2%) with a solitary meningioma (P = 0.679). Median recurrence-free survival was 89 months (95% CI 76-104) with no difference between the two groups (P = 0.209). Mean overall survival was 132 months (95% CI 127-138) with no difference between the two groups (P = 0.860). One patient with multiple meningioma developed two further new meningioma 36 months following diagnosis. CONCLUSION: Sporadic multiple meningioma may not have worse clinical outcomes. Management of patients with sporadic multiple meningioma should be tailored towards the symptomatic meningioma or high-risk asymptomatic meningioma.
引用
- Islim AI, Lee JX, Mustafa MA, et al. Sporadic multiple intracranial meningioma does not infer worse patient outcomes: results from a case control study. J Neurooncol. 2022. PMID: 36378400. doi:10.1007/s11060-022-04184-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。